Innodia Clinical Trials

From start on, a major goal of INNODIA was to undertake clinical intervention studies and to pave the way for the development of novel treatments to prevent and cure Type 1 Diabetes.

Since 2020, INNODIA performed 4 mechanistic-based clinical studies, using a Master-Protocol established within INNODIA.

People with newly diagnosed type 1 diabetes could take part in research that aims to generate knowledge helping to arrest further disease development. Type 1 diabetes is an autoimmune disease in which immune cells of the body attack specifically the insulin producing beta cells in the pancreas, leading to their steady decline. Decrease in functional beta cell mass leads to loss of blood glucose control. Regaining blood glucose control via multiple daily insulin injections is challenging and often insufficient leading to the development of numerous complications.

The goal of the performed clinical intervention trials, conducted within INNODIA, is to halt the further decline in beta cell functionality in people with newly diagnosed T1D, addressing the immune system or the beta cells by different treatment modalities.

When someone is first diagnosed with T1D, half of the pancreatic insulin producing beta cells are still working. The beta cells have not yet been all destroyed.

Therefore, participants had to been newly diagnosed people with T1D (diagnosed over the past 6 weeks) to guarantee the highest benefit on preserved insulin producing beta cells.

The dream ultimately remains to halt further disease progression!

PAC

A clear priority of INNODIA is to keep the needs and concerns of people living with Type 1 Diabetes at the center of the project. Therefore, INNODIA has a very active and dedicated Patient Advisory Committee (PAC).

Especially when it comes to clinical trials, the role of the PAC becomes most important. People with T1D and their relatives need a strong voice! Their advice and experiences helps the discussion of how the trials should be designed - What do we ask people to do - How do we explain things to the participants - Which collaterals should we use - Are we measuring the things that matter to people (hypo glycaemia, the effort spent on diabetes, satisfactions, challenges, difficulties …?)

Innodia Clinical Trials

PAC

Why participate in a trial?